Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 282
interventional 249
Observational 31
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 138
Drug|placebo 70
Other 9
Behavioral 7
Device 5
Procedure 4
Biological 2
Device|Drug 2
Device|placebo 2
Dietary Supplement|placebo 2
Biological|placebo 1
Combination Product|placebo 1
Device|Diagnostic Test 1
Device|Other 1
Dietary Supplement 1
Drug|Other 1
Drug|Procedure 1
Other|placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
NA 37
Korea, Republic of 30
Japan 26
United States 23
China 19
Germany 13
Denmark 8
France 7
Belgium 3
Germany|Switzerland 3
India 3
Taiwan 3
Turkey 3
Brazil 2
Canada 2
China|Japan|Korea, Republic of|Taiwan|Thailand 2
Greece 2
Switzerland 2
United States|Argentina|Mexico 2
United States|Chile|Mexico 2
NA 1
Argentina|Chile|Ecuador|Finland|France|Germany|Italy|Norway|Spain|Sweden|Switzerland|Turkey 1
Argentina|United States|Brazil|Mexico|Peru|Puerto Rico 1
Austria|Germany|Italy|Netherlands|Portugal|Spain|Switzerland|United Kingdom 1
Bangladesh 1
Belgium|France|Germany|United Kingdom 1
Bulgaria|Czechia|France|Germany|Poland|Spain|Ukraine 1
Bulgaria|Estonia|Finland|Germany|Netherlands|Poland|Russian Federation|Serbia|Slovakia|Sweden 1
Chile 1
China|Hong Kong|Japan|Korea, Republic of|Philippines|Taiwan|Thailand 1
China|Hong Kong|Korea, Republic of|Philippines|Singapore|Taiwan|Thailand 1
China|India|Thailand 1
China|Japan|Korea, Republic of|Malaysia|Philippines|Taiwan 1
China|Taiwan|Thailand 1
Colombia|Ecuador|Hong Kong|Indonesia|Malaysia|Philippines|Singapore|Taiwan|Thailand|Turkey| 1
Czech Republic|Finland|France|Germany|Hungary|Italy|Poland|Slovakia|Spain|Sweden 1
Egypt 1
Finland 1
Finland|United States|Argentina|Canada|Denmark|France|Germany|Hungary|Italy|Latvia|Lithuania|Netherlands|Poland|Russian Federation|Slovakia|Spain|Sweden|Taiwan 1
France|Austria|Belgium|Germany|Italy|Netherlands|Portugal|Switzerland|United Kingdom 1
France|Hungary|Romania|Slovakia 1
Germany|Russian Federation|United Kingdom 1
Iran, Islamic Republic of 1
Israel 1
Israel|Serbia 1
Italy 1
Italy|Lithuania|Netherlands|Bulgaria|Estonia|France|Germany|Hungary|Poland|Serbia|Slovakia|Spain|Sweden|United Kingdom 1
Mexico 1
Netherlands 1
Netherlands|Argentina|Czech Republic|Germany|Iceland|Italy|Poland|Slovakia 1
Netherlands|Austria|Belgium|Bulgaria|Czechia|Denmark|France|Germany|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine 1
Netherlands|Belgium|Germany|Slovakia 1
Norway 1
Russian Federation 1
Singapore 1
Slovakia 1
Slovakia|Belgium|Bulgaria|Czechia|Denmark|Germany|Hungary|Italy|Latvia|Netherlands|Poland|Romania|Russian Federation|Spain|Ukraine 1
South Africa 1
Spain 1
Sweden 1
Thailand 1
United Kingdom|Austria|Germany|Netherlands|Poland 1
United States|Argentina|Australia|Canada|Colombia|Denmark|Finland|Greece|Italy|Mexico|Panama|Peru|Romania|Russian Federation|South Africa|Spain|Sweden|Taiwan 1
United States|Argentina|Belgium|Brazil|Canada|Italy|Korea, Republic of|Lithuania|Russian Federation|South Africa|Spain|Ukraine|United Kingdom 1
United States|Argentina|Colombia|Finland|Germany|Italy|Russian Federation|Spain|Sweden 1
United States|Argentina|Colombia|France|Germany|India|Spain 1
United States|Belgium|Canada|Germany|Poland|United Kingdom 1
United States|Belgium|Egypt|Germany|Poland|Slovakia|Spain|Turkey 1
United States|Canada 1
United States|Canada|Israel|Puerto Rico 1
United States|Canada|Puerto Rico 1
United States|Chile|Mexico|Peru 1
United States|Germany 1
United States|Germany|Spain 1
United States|Puerto Rico 1
United States|Russian Federation 1
Zambia 1

Sites per Study

Site_count Study_Count
1 160
2 7
3 4
4 6
5 3
6 2
7 1
8 5
9 1
10 1
11 2
12 2
13 3
18 3
20 1
22 2
23 1
24 2
26 2
28 1
30 1
32 1
33 1
34 1
38 2
39 1
41 2
42 1
43 1
45 1
46 1
48 1
50 2
53 1
55 1
57 1
60 1
61 1
64 1
72 1
76 1
78 1
79 1
80 1
82 1
85 1
87 1
88 1
91 1
94 1
99 1
108 1
117 1
131 1
133 1
157 1
182 1

Phase

Phase Study_Count
Phase 3 100
Phase 4 42
Phase 2 38
N/A 36
Phase 1 25
Phase 2/Phase 3 4
Phase 1/Phase 2 3
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 29
2 105
3 35
4 19
5 13
6 5
7 4
8 3
9 4
16 1
NA 31

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 192 8.0000 14.00 22 20.0000 120.00 20.0000 13.000
1st Qu. 192 41.5000 23.00 46 80.2500 294.75 282.0000 98.000
Median 192 68.5000 34.00 70 189.0000 515.50 418.0000 177.000
Mean 192 371.8889 45.32 60 350.4211 656.25 637.2121 1418.049
3rd Qu. 192 179.0000 49.00 79 435.0000 877.00 838.5000 506.000
Max. 192 8000.0000 300.00 88 1659.0000 1474.00 2775.0000 21983.000

Trial Group Type

group_type Group_Count
Experimental 345
Active Comparator 182
Placebo Comparator 54
NA 31
Other 20
No Intervention 11
Sham Comparator 7

Intervention Model

intervention_model Study_Count
Parallel Assignment 169
Single Group Assignment 37
Crossover Assignment 31
Factorial Assignment 11
NA 1

Primary Purpose

primary_purpose Study_Count
Treatment 208
NA 18
Prevention 6
Supportive Care 6
Diagnostic 4
Basic Science 3
Health Services Research 2
Other 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
NA 8
Korea, Republic of 3
Switzerland 3
China 2
France 2
Poland 2
United States 2
Czech Republic 1
Denmark 1
Finland 1
India 1
Italy 1
Japan 1
Latvia 1
Pakistan 1
Romania 1

Sites per Study

Site_count Study_Count
1 23
2 2
3 1
4 1
8 1
16 1
99 1
134 1

Enrollment Metrics

Measure Observational
Min 38.000
1st Qu 96.000
Median 800.000
Mean 4164.355
3rd Qu 2659.000
Max 33247.000

Observation Model

observational_model Study_Count
Cohort 17
Case-Only 3
Other 3
Case-Control 2
Case Control 2
NA 2
Case Control, Natural History 1
Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 24
Cross-Sectional 3
Cross-Sectional, Prospective 1
Longitudinal, Prospective 1
Other 1
NA 1

Registries

Studies by Country

Country Study_Count
Korea, Republic of 1
NA 1

Sites per Study

Site_count Study_Count
1 2

Enrollment Metrics

Measure Registries
Min 151.0
1st Qu 263.5
Median 376.0
Mean 376.0
3rd Qu 488.5
Max 601.0

Registry Model

observational_model Study_Count
Cohort 2

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
12 Months 1
2 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04460300 Effects of Aromatherapy in Hypertensive Individuals https://ClinicalTrials.gov/show/NCT04460300 Recruiting Abant Izzet Baysal University 2020-08-03
NCT04459741 HIV, Immune Activation and Salt Sensitive Hypertension https://ClinicalTrials.gov/show/NCT04459741 Completed Mulungushi University 2019-12-31
NCT03503773 The TARGET BP OFF-MED Trial https://ClinicalTrials.gov/show/NCT03503773 Recruiting Ablative Solutions, Inc. 2020-09-30
NCT03338426 A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia https://ClinicalTrials.gov/show/NCT03338426 Completed Boryung Pharmaceutical Co., Ltd 2019-04-22
NCT03246555 Fimasartan in the Senior Subjects https://ClinicalTrials.gov/show/NCT03246555 Completed Boryung Pharmaceutical Co., Ltd 2019-08-19
NCT03206944 Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects https://ClinicalTrials.gov/show/NCT03206944 Completed Poznan University of Medical Sciences 2017-01-01
NCT03186742 Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy https://ClinicalTrials.gov/show/NCT03186742 Completed Poznan University of Medical Sciences 2017-01-01
NCT03179163 Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans https://ClinicalTrials.gov/show/NCT03179163 Recruiting Penn State University 2020-08-31
NCT03156842 Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia https://ClinicalTrials.gov/show/NCT03156842 Completed Boryung Pharmaceutical Co., Ltd 2018-12-07
NCT03105687 Effectiveness of SMS Reminders of Blood Pressure-lowering Drugs Intake https://ClinicalTrials.gov/show/NCT03105687 Completed Comenius University 2018-01-10
NCT03015311 Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients https://ClinicalTrials.gov/show/NCT03015311 Active, not recruiting Chinese Academy of Medical Sciences, Fuwai Hospital 2021-12-31
NCT02996916 Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue https://ClinicalTrials.gov/show/NCT02996916 Recruiting Kurume University 2018-12-31
NCT02944734 Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02944734 Completed Shin Poong Pharmaceutical Co. Ltd. 2015-12-31
NCT02848170 Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02848170 Completed Daiichi Sankyo, Inc. 2017-04-30
NCT02839382 The Northwest Coalition for Primary Care Practice Support https://ClinicalTrials.gov/show/NCT02839382 Completed Kaiser Permanente 2018-05-01
NCT02822222 Safety Study of RMJH-111b to Treat Essential Hypertension https://ClinicalTrials.gov/show/NCT02822222 Completed RMJ Holdings, LLC 2016-07-31
NCT02738632 Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients https://ClinicalTrials.gov/show/NCT02738632 Completed IlDong Pharmaceutical Co Ltd 2016-08-31
NCT02722265 Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02722265 Completed Daiichi Sankyo, Inc. 2017-07-08
NCT02687178 Canrenone as Add-on in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02687178 Completed University of Pavia 2015-10-31
NCT02641821 Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension https://ClinicalTrials.gov/show/NCT02641821 Recruiting Peking University First Hospital 2019-12-31
NCT02612298 Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate https://ClinicalTrials.gov/show/NCT02612298 Completed Sumitomo Pharmaceutical (Suzhou) Co., Ltd. 2018-09-13
NCT02603809 Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT02603809 Completed Idorsia Pharmaceuticals Ltd. 2017-02-28
NCT02031861 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT02031861 Completed Shanghai Shyndec Pharmaceutical Co., Ltd. 2014-07-31
NCT02517866 Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia https://ClinicalTrials.gov/show/NCT02517866 Completed Takeda 2016-11-15
NCT02480764 Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension https://ClinicalTrials.gov/show/NCT02480764 Completed Takeda 2017-09-22
NCT02466490 Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02466490 Completed Stendhal Americas, S.A. 2014-02-28
NCT02433119 The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy https://ClinicalTrials.gov/show/NCT02433119 Completed Dong-A ST Co., Ltd. 2016-09-08
NCT02419235 The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension https://ClinicalTrials.gov/show/NCT02419235 Completed University of Johannesburg 2015-03-31
NCT02412761 Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension https://ClinicalTrials.gov/show/NCT02412761 Completed The University of Texas Health Science Center, Houston 2016-07-31
NCT02345044 A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects https://ClinicalTrials.gov/show/NCT02345044 Completed Daiichi Sankyo, Inc. 2015-08-31
NCT02322450 Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02322450 Completed Quantum Genomics SA 2016-04-30
NCT02277691 A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT02277691 Completed Takeda 2016-04-25
NCT02269176 Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension https://ClinicalTrials.gov/show/NCT02269176 Completed Boehringer Ingelheim 2001-01-31
NCT02245230 Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension https://ClinicalTrials.gov/show/NCT02245230 Recruiting Vanderbilt University Medical Center 2021-12-31
NCT02242370 Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02242370 Completed Boehringer Ingelheim 2000-11-30
NCT02211352 Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension https://ClinicalTrials.gov/show/NCT02211352 Completed Daegu Catholic University Medical Center 2013-12-31
NCT02206659 Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT02206659 Completed Boehringer Ingelheim 2001-02-28
NCT02200926 Non-pharmacological Treatment for Essential Isolated Systolic Hypertension in Elderly https://ClinicalTrials.gov/show/NCT02200926 Completed Khon Kaen University 2015-11-30
NCT02194465 A Study of LY2623091 in Participants With High Blood Pressure https://ClinicalTrials.gov/show/NCT02194465 Completed Eli Lilly and Company 2015-03-31
NCT02184858 Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension https://ClinicalTrials.gov/show/NCT02184858 Completed University Ghent 2017-05-08
NCT02183701 Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT02183701 Completed Boehringer Ingelheim 1998-12-31
NCT02177448 BIBR 277 Capsule in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02177448 Completed Boehringer Ingelheim 1999-09-30
NCT02166814 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia https://ClinicalTrials.gov/show/NCT02166814 Completed Boryung Pharmaceutical Co., Ltd 2015-09-30
NCT02152306 Fimasartan/Amlodipine Combination Phase III https://ClinicalTrials.gov/show/NCT02152306 Completed Boryung Pharmaceutical Co., Ltd 2015-03-31
NCT02079805 A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R https://ClinicalTrials.gov/show/NCT02079805 Completed Takeda 2016-04-30
NCT02072330 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. https://ClinicalTrials.gov/show/NCT02072330 Completed Takeda 2013-12-31
NCT02062645 Study of Efficacy and Safety of CVAA489 in Hypertensive Patients https://ClinicalTrials.gov/show/NCT02062645 Completed Novartis 2015-09-30
NCT02058446 PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension https://ClinicalTrials.gov/show/NCT02058446 Completed TSH Biopharm Corporation Limited 2014-03-31
NCT01307046 MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) https://ClinicalTrials.gov/show/NCT01307046 Completed Merck Sharp & Dohme Corp. 2012-02-07
NCT01307033 A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) https://ClinicalTrials.gov/show/NCT01307033 Completed Merck Sharp & Dohme Corp. 2012-12-04
NCT01303783 Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01303783 Completed Bayer 2012-05-31
NCT01302691 MK-0954E Study in Participants With Hypertension (MK-0954E-357) https://ClinicalTrials.gov/show/NCT01302691 Completed Merck Sharp & Dohme Corp. 2012-04-01
NCT01299376 MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356) https://ClinicalTrials.gov/show/NCT01299376 Completed Merck Sharp & Dohme Corp. 2011-11-16
NCT01294215 High Dose BAYA1040_Nifedipine: a Long Term Combination Study https://ClinicalTrials.gov/show/NCT01294215 Completed Bayer 2011-11-30
NCT01289899 Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects https://ClinicalTrials.gov/show/NCT01289899 Completed Boryung Pharmaceutical Co., Ltd 2004-02-29
NCT01289886 Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects https://ClinicalTrials.gov/show/NCT01289886 Completed Boryung Pharmaceutical Co., Ltd 2003-11-30
NCT01289132 Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension https://ClinicalTrials.gov/show/NCT01289132 Completed Takeda 2008-07-31
NCT01287260 High Dose BAYA1040_Nifedipine: a Dose-comparative Study https://ClinicalTrials.gov/show/NCT01287260 Completed Bayer 2011-08-31
NCT01904695 Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study https://ClinicalTrials.gov/show/NCT01904695 Completed China Academy of Chinese Medical Sciences 2015-10-31
NCT01900184 Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT01900184 Completed Quantum Genomics SA 2013-03-31
NCT01900171 Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo https://ClinicalTrials.gov/show/NCT01900171 Completed Quantum Genomics SA 2012-05-31
NCT01878201 A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT01878201 Completed Boryung Pharmaceutical Co., Ltd 2014-02-28
NCT01873885 Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomeraâ„¢ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension https://ClinicalTrials.gov/show/NCT01873885 Completed PhaseBio Pharmaceuticals Inc. 2014-03-31
NCT01842256 Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin. https://ClinicalTrials.gov/show/NCT01842256 Completed Chong Kun Dang Pharmaceutical 2013-05-31
NCT01842230 Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine https://ClinicalTrials.gov/show/NCT01842230 Completed Chong Kun Dang Pharmaceutical 2013-05-31
NCT01838850 Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy https://ClinicalTrials.gov/show/NCT01838850 Completed Daiichi Sankyo, Inc. 2014-08-31
NCT01788358 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension https://ClinicalTrials.gov/show/NCT01788358 Completed Bayer 2014-05-01
NCT01785472 Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01785472 Completed Novartis 2014-08-31
NCT01762436 Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01762436 Completed Ruijin Hospital 2012-02-29
NCT01756430 Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01756430 Completed Chong Kun Dang Pharmaceutical 2013-09-30
NCT01701726 Effect of Acupuncture on Patients With Mild Hypertension https://ClinicalTrials.gov/show/NCT01701726 Completed Chengdu University of Traditional Chinese Medicine 2016-02-29
NCT01679652 The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01679652 Completed Regional Hospital Holstebro 2013-09-30
NCT01672476 A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT01672476 Completed Boryung Pharmaceutical Co., Ltd 2013-03-31
NCT01667614 Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure https://ClinicalTrials.gov/show/NCT01667614 Completed Tehran University of Medical Sciences 2012-03-31
NCT01665534 Inflammatory Response to Salt in Essential Hypertension https://ClinicalTrials.gov/show/NCT01665534 Completed Fondazione C.N.R./Regione Toscana “G. Monasterio”, Pisa, Italy 2011-03-31
NCT01663233 Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine https://ClinicalTrials.gov/show/NCT01663233 Completed Novartis 2013-05-31
NCT01631370 The Effects of Renal Denervation on Insulin Sensitivity https://ClinicalTrials.gov/show/NCT01631370 Completed University of Aarhus 2015-03-30
NCT01631227 Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension https://ClinicalTrials.gov/show/NCT01631227 Completed Abbott 2013-04-30
NCT01615198 Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01615198 Completed Novartis 2013-07-31
NCT01599104 Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01599104 Completed Novartis 2013-04-30
NCT01566188 Vascular Impact of Omega-3 in Metabolic Syndrome https://ClinicalTrials.gov/show/NCT01566188 Completed University Hospital, Rouen 2014-01-31
NCT01556997 Perindopril Amlodipine for the Treatment of Hypertension https://ClinicalTrials.gov/show/NCT01556997 Completed Symplmed Pharmaceuticals LLC 2013-02-28
NCT01541943 Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia https://ClinicalTrials.gov/show/NCT01541943 Completed HanAll BioPharma Co., Ltd. 2014-11-30
NCT01523067 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension https://ClinicalTrials.gov/show/NCT01523067 Completed PhaseBio Pharmaceuticals Inc. 2012-12-31
NCT01518855 Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01518855 Completed Bayer 2005-04-30
NCT01459900 Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial https://ClinicalTrials.gov/show/NCT01459900 Completed Aarhus University Hospital Skejby 2015-02-28
NCT01456169 A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone https://ClinicalTrials.gov/show/NCT01456169 Completed Takeda 2012-12-31
NCT01442116 Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential Hypertension https://ClinicalTrials.gov/show/NCT01442116 Completed Mustafa Kemal University 2009-12-31
NCT01417221 Renal Sympathetic Modification in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01417221 Recruiting The Second Affiliated Hospital of Chongqing Medical University 2019-12-31
NCT01355367 High Dose BAYA1040 CR: a Long Term Extension Study https://ClinicalTrials.gov/show/NCT01355367 Completed Bayer 2011-09-30
NCT01350609 Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed https://ClinicalTrials.gov/show/NCT01350609 Completed Bayer 2011-08-31
NCT01342614 The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension https://ClinicalTrials.gov/show/NCT01342614 Completed China-Japan Friendship Hospital 2009-08-31
NCT04151537 Personal Activity Intelligence in the Treatment of High Blood Pressure https://ClinicalTrials.gov/show/NCT04151537 Recruiting Norwegian University of Science and Technology 2020-09-30
NCT04119999 A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling https://ClinicalTrials.gov/show/NCT04119999 Recruiting National University, Singapore 2023-08-31
NCT04103411 Effect of High-Intensity Interval Training Compared to Hydrochlorothiazide on Ambulatory Blood Pressure https://ClinicalTrials.gov/show/NCT04103411 Recruiting Montreal Heart Institute 2021-06-01
NCT03991442 BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination https://ClinicalTrials.gov/show/NCT03991442 Recruiting Boryung Pharmaceutical Co., Ltd 2021-09-01
NCT03928158 LCZ696 in Advanced LV Hypertrophy and HFpEF https://ClinicalTrials.gov/show/NCT03928158 Recruiting National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 2020-11-30
NCT03928145 Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension. https://ClinicalTrials.gov/show/NCT03928145 Recruiting Hospital de Clinicas de Porto Alegre 2021-07-31
NCT03924115 Evaluation of a Transmedial Psychoeducational Program to Improve Pharmacological Adherence https://ClinicalTrials.gov/show/NCT03924115 Completed Universidad de Concepcion 2018-12-31
NCT03908710 The Accumbo Home Blood Pressure Trial https://ClinicalTrials.gov/show/NCT03908710 Completed Accumbo AB 2018-10-30
NCT03901183 Plant-based Nutrition for Patients With Cardiovascular Risk Factors https://ClinicalTrials.gov/show/NCT03901183 Recruiting Charite University, Berlin, Germany 2020-07-31
NCT03897868 A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT03897868 Recruiting Hanmi Pharmaceutical Company Limited 2019-11-30
NCT03858595 Optimizing Gestational Weight Gain, Birth Weight and Other Perinatal Outcomes Among Pregnant Women at Risk of Hypertension in Pregnancy https://ClinicalTrials.gov/show/NCT03858595 Recruiting International Centre for Diarrhoeal Disease Research, Bangladesh 2020-10-31
NCT03857490 Heat Therapy in Older Hypertensive Women https://ClinicalTrials.gov/show/NCT03857490 Recruiting University of Texas Southwestern Medical Center 2023-09-30
NCT03803306 Vedic Medical Astrology in Essential Hypertension https://ClinicalTrials.gov/show/NCT03803306 Completed NMP Medical Research Institute 2018-12-15
NCT03778489 Impact of Aerobic Exercise Training on Sympathetic Vasoconstriction and Vascular Function in Essential Hypertension https://ClinicalTrials.gov/show/NCT03778489 Recruiting University of Copenhagen 2020-01-01
NCT03756103 Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients https://ClinicalTrials.gov/show/NCT03756103 Recruiting Shanghai Pharmaceuticals Holding Co., Ltd 2020-06-30
NCT03722199 Effects of Flavanoids in Essential Hypertension, Type 2 Diabetes and Healthy Persons https://ClinicalTrials.gov/show/NCT03722199 Active, not recruiting University Ghent 2020-06-20
NCT03566654 Clinical Trial on Remote Ischemic Conditioning and Hypertension(HOPE) https://ClinicalTrials.gov/show/NCT03566654 Recruiting Capital Medical University 2019-12-31
NCT03514641 An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension https://ClinicalTrials.gov/show/NCT03514641 Completed Theracos 2018-11-30
NCT03511313 Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension https://ClinicalTrials.gov/show/NCT03511313 Recruiting Synaptic Medical Limited 2020-06-30
NCT03492892 Use of Metabolomics to Differentiate the Antihypertensive Effect of Acupuncture From Sham Acupuncture in Hypertensives https://ClinicalTrials.gov/show/NCT03492892 Completed The University of Hong Kong 2016-08-19
NCT03480217 Implementing Hypertension Screening Guidelines in Primary Care https://ClinicalTrials.gov/show/NCT03480217 Recruiting Columbia University 2019-04-02
NCT03479697 HIRREM for Stage 1 Primary Hypertension https://ClinicalTrials.gov/show/NCT03479697 Recruiting Wake Forest University Health Sciences 2020-07-31
NCT01264692 Essential Hypertension https://ClinicalTrials.gov/show/NCT01264692 Completed Idorsia Pharmaceuticals Ltd. 2012-01-31
NCT01258673 A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy https://ClinicalTrials.gov/show/NCT01258673 Completed Boryung Pharmaceutical Co., Ltd 2011-12-31
NCT01256411 A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01256411 Completed Novartis 2012-04-30
NCT01251146 A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System’s Activity in Subjects With Essential Hypertension https://ClinicalTrials.gov/show/NCT01251146 Completed Merck KGaA, Darmstadt, Germany 2012-02-29
NCT01241487 A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy https://ClinicalTrials.gov/show/NCT01241487 Completed Novartis 2011-01-31
NCT01237873 Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01237873 Completed Novartis 2012-02-29
NCT01237223 Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01237223 Completed Novartis 2011-05-31
NCT01227603 Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions https://ClinicalTrials.gov/show/NCT01227603 Completed Bayer 2011-03-31
NCT01198249 Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension https://ClinicalTrials.gov/show/NCT01198249 Completed Yonsei University 2011-02-28
NCT01195805 The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables https://ClinicalTrials.gov/show/NCT01195805 Completed Regional Hospital Holstebro 2015-08-31
NCT01193101 Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01193101 Completed Novartis 2011-04-30
NCT01180413 Intensive Vasodilator Therapy in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01180413 Completed Aarhus University Hospital 2012-04-30
NCT01146938 A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers https://ClinicalTrials.gov/show/NCT01146938 Completed Boryung Pharmaceutical Co., Ltd 2011-02-28
NCT01135212 The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT01135212 Completed Boryung Pharmaceutical Co., Ltd 2011-04-30
NCT01131546 Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01131546 Completed Jiangsu Simcere Pharmaceutical Co., Ltd. 2011-03-31
NCT01126684 Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion https://ClinicalTrials.gov/show/NCT01126684 Completed Aristotle University Of Thessaloniki 2009-12-31
NCT01122251 Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01122251 Completed LG Life Sciences 2010-05-31
NCT01120990 Hybrid Blood Pressure Monitor Validation https://ClinicalTrials.gov/show/NCT01120990 Completed University of Athens 2010-06-30
NCT01113047 Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine https://ClinicalTrials.gov/show/NCT01113047 Completed Novartis 2010-10-31
NCT01093807 Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01093807 Completed Recordati Industria Chimica e Farmaceutica S.p.A. 2011-03-31
NCT01042392 Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients https://ClinicalTrials.gov/show/NCT01042392 Completed Novartis 2011-01-31
NCT01033071 Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension. https://ClinicalTrials.gov/show/NCT01033071 Completed Takeda 2010-10-31
NCT01013155 Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions https://ClinicalTrials.gov/show/NCT01013155 Completed West-Ward Pharmaceutical 2007-05-31
NCT01012687 Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions https://ClinicalTrials.gov/show/NCT01012687 Completed West-Ward Pharmaceutical 2007-05-31
NCT01001572 Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT01001572 Completed Novartis 2010-05-31
NCT00996281 Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00996281 Completed Takeda 2011-11-30
NCT00991783 A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00991783 Completed Boryung Pharmaceutical Co., Ltd 2009-11-30
NCT00991705 A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00991705 Completed Boryung Pharmaceutical Co., Ltd 2009-09-30
NCT00942344 Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00942344 Completed Hanmi Pharmaceutical Company Limited 2007-12-31
NCT00940680 Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00940680 Completed Hanmi Pharmaceutical Company Limited 2008-11-30
NCT00940667 Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00940667 Completed Hanmi Pharmaceutical Company Limited 2008-12-31
NCT00938262 A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00938262 Completed Boryung Pharmaceutical Co., Ltd 2009-06-30
NCT00938197 A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00938197 Completed Boryung Pharmaceutical Co., Ltd 2009-08-31
NCT00938132 A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00938132 Completed Boryung Pharmaceutical Co., Ltd 2009-09-30
NCT00937651 Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K) https://ClinicalTrials.gov/show/NCT00937651 Completed Boryung Pharmaceutical Co., Ltd 2006-06-30
NCT00937534 Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers https://ClinicalTrials.gov/show/NCT00937534 Completed Boryung Pharmaceutical Co., Ltd 2009-08-31
NCT00923611 Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients https://ClinicalTrials.gov/show/NCT00923611 Completed Boryung Pharmaceutical Co., Ltd 2008-06-30
NCT00923091 Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension https://ClinicalTrials.gov/show/NCT00923091 Completed Daiichi Sankyo, Inc. 2011-01-31
NCT00922441 A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00922441 Completed Boryung Pharmaceutical Co., Ltd 2009-08-31
NCT00923533 A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00923533 Completed Boryung Pharmaceutical Co., Ltd 2009-05-31
NCT00902538 Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension https://ClinicalTrials.gov/show/NCT00902538 Completed Daiichi Sankyo, Inc. 2010-09-30
NCT00890591 Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension https://ClinicalTrials.gov/show/NCT00890591 Completed Daiichi Sankyo, Inc. 2007-06-30
NCT00872586 Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00872586 Completed Daiichi Sankyo, Inc. 2007-07-31
NCT00865501 Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease https://ClinicalTrials.gov/show/NCT00865501 Completed University of Erlangen-Nürnberg Medical School 2009-12-31
NCT00858702 Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension https://ClinicalTrials.gov/show/NCT00858702 Completed Daiichi Sankyo, Inc. 2005-07-31
NCT00857285 Olmesartan Medoxomil Versus Losartan in Patients With Hypertension https://ClinicalTrials.gov/show/NCT00857285 Completed Daiichi Sankyo, Inc. 2003-08-31
NCT00856271 Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00856271 Completed Daiichi Sankyo, Inc. 2005-02-28
NCT00846365 Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension https://ClinicalTrials.gov/show/NCT00846365 Completed Takeda 2010-06-30
NCT03276598 A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension https://ClinicalTrials.gov/show/NCT03276598 Completed Helsinki University Central Hospital 2004-04-01
NCT01527760 Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension https://ClinicalTrials.gov/show/NCT01527760 Completed Fr Muller Homoeopathic Medical College 2011-08-31
NCT03258489 Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients https://ClinicalTrials.gov/show/NCT03258489 Completed Universidade Federal de Santa Maria 2019-12-09
NCT02890173 Study of CS-3150 in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02890173 Completed Daiichi Sankyo, Inc. 2017-07-11
NCT02579356 To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT02579356 Completed Samil Pharmaceutical Co., Ltd. 2014-08-31
NCT00779181 A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension https://ClinicalTrials.gov/show/NCT00779181 Completed Addrenex Pharmaceuticals, Inc. 2008-12-31
NCT00765947 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension https://ClinicalTrials.gov/show/NCT00765947 Completed Novartis 2009-08-31
NCT00760214 Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension https://ClinicalTrials.gov/show/NCT00760214 Completed Takeda 2009-04-30
NCT00759551 Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension https://ClinicalTrials.gov/show/NCT00759551 Completed Takeda 2005-06-30
NCT00758524 A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00758524 Completed Novartis 2009-07-31
NCT00751751 Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly https://ClinicalTrials.gov/show/NCT00751751 Completed Daiichi Sankyo, Inc. 2005-04-30
NCT00739973 Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension https://ClinicalTrials.gov/show/NCT00739973 Completed Novartis 2009-05-31
NCT00710372 Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension https://ClinicalTrials.gov/show/NCT00710372 Completed Cytos Biotechnology AG 2009-07-31
NCT00709930 Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00709930 Completed Kyoto University 2008-08-31
NCT00706134 Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study https://ClinicalTrials.gov/show/NCT00706134 Completed Novartis 2009-04-30
NCT00701649 Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension https://ClinicalTrials.gov/show/NCT00701649 Completed Cytos Biotechnology AG 2009-03-31
NCT00699192 Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension https://ClinicalTrials.gov/show/NCT00699192 Completed Novartis 2009-05-31
NCT00696436 An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension. https://ClinicalTrials.gov/show/NCT00696436 Completed Takeda 2009-08-31
NCT00696384 A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00696384 Completed Takeda 2009-04-30
NCT00696241 Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00696241 Completed Takeda 2008-10-31
NCT00695955 One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00695955 Completed Takeda 2010-05-31
NCT00687973 Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg https://ClinicalTrials.gov/show/NCT00687973 Completed Novartis 2009-01-31
NCT00667719 A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00667719 Completed Novartis 2009-10-31
NCT00662896 To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension https://ClinicalTrials.gov/show/NCT00662896 Completed NicOx 2008-09-30
NCT00654875 Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. https://ClinicalTrials.gov/show/NCT00654875 Completed Novartis 2008-11-30
NCT00631917 A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension https://ClinicalTrials.gov/show/NCT00631917 Completed Novartis 2009-09-30
NCT00624065 Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure https://ClinicalTrials.gov/show/NCT00624065 Completed GlaxoSmithKline 2008-08-31
NCT00591773 Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00591773 Completed Takeda 2009-03-31
NCT00591578 Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00591578 Completed Takeda 2009-09-30
NCT00591266 Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00591266 Completed Takeda 2009-03-31
NCT00591253 Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension https://ClinicalTrials.gov/show/NCT00591253 Completed Takeda 2009-04-30
NCT00553865 Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets https://ClinicalTrials.gov/show/NCT00553865 Completed Jeil Pharmaceutical Co., Ltd. 2008-10-31
NCT00549770 Efficacy and Safety of LCZ696A in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00549770 Completed Novartis 2008-07-31
NCT00546754 BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) https://ClinicalTrials.gov/show/NCT00546754 Completed Merck Sharp & Dohme Corp. 2009-04-01
NCT00529451 Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg https://ClinicalTrials.gov/show/NCT00529451 Completed Novartis 2008-07-31
NCT00509470 Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine https://ClinicalTrials.gov/show/NCT00509470 Completed Tokyo University 2012-06-30
NCT00500786 Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb https://ClinicalTrials.gov/show/NCT00500786 Completed Cytos Biotechnology AG 2006-09-30
NCT00461903 Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00461903 Completed Montreal Heart Institute 2015-09-30
NCT00457483 Nijmegen Antihypertensive Management Improvement Study https://ClinicalTrials.gov/show/NCT00457483 Completed Radboud University 2010-12-31
NCT00446524 Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301) https://ClinicalTrials.gov/show/NCT00446524 Completed Novartis 2008-10-31
NCT00441350 Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension https://ClinicalTrials.gov/show/NCT00441350 Completed Menarini Group 2008-05-31
NCT00438945 The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00438945 Completed Regional Hospital Holstebro NA
NCT00437645 Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00437645 Completed Novartis 2007-11-30
NCT00430950 Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension https://ClinicalTrials.gov/show/NCT00430950 Completed Daiichi Sankyo, Inc. 2008-05-31
NCT00430508 Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension https://ClinicalTrials.gov/show/NCT00430508 Completed Daiichi Sankyo, Inc. 2008-03-31
NCT00425373 Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00425373 Completed Novartis 2008-03-31
NCT00424541 Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00424541 Completed Novartis NA
NCT00415038 Efficacy of Rostafuroxin in the Treatment of Essential Hypertension https://ClinicalTrials.gov/show/NCT00415038 Completed sigma-tau i.f.r. S.p.A. 2007-04-30
NCT00408512 Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study https://ClinicalTrials.gov/show/NCT00408512 Completed Federico II University 2009-12-31
NCT00367094 Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00367094 Completed Novartis NA
NCT00355589 Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension https://ClinicalTrials.gov/show/NCT00355589 Completed Pfizer 2007-03-31
NCT00345150 Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls https://ClinicalTrials.gov/show/NCT00345150 Completed Regional Hospital Holstebro NA
NCT00345124 The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential Hypertension https://ClinicalTrials.gov/show/NCT00345124 Completed Regional Hospital Holstebro 2009-05-31
NCT00344110 Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00344110 Completed Novartis 2007-04-30
NCT00343551 Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension. https://ClinicalTrials.gov/show/NCT00343551 Completed Novartis 2007-01-31
NCT00338936 Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) https://ClinicalTrials.gov/show/NCT00338936 Completed Novartis 2007-09-30
NCT00328965 Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea https://ClinicalTrials.gov/show/NCT00328965 Completed GlaxoSmithKline 2006-05-31
NCT00311740 A Study of VAH631 in Patients With Essential Hypertension (Factorial Study) https://ClinicalTrials.gov/show/NCT00311740 Completed Novartis 2006-09-30
NCT00311155 Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension https://ClinicalTrials.gov/show/NCT00311155 Completed Daiichi Sankyo, Inc. 2008-04-30
NCT00295555 Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy https://ClinicalTrials.gov/show/NCT00295555 Completed Yokohama City University Medical Center NA
NCT00288184 Uric Acid in Essential Hypertension in Children https://ClinicalTrials.gov/show/NCT00288184 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2007-03-31
NCT00257491 Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00257491 Completed Boehringer Ingelheim 2006-08-31
NCT00254475 A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00254475 Completed Novartis 2006-09-30
NCT00246584 A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US) https://ClinicalTrials.gov/show/NCT00246584 Completed Novartis NA
NCT00236665 A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00236665 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NA
NCT00220233 Olmesartan as an add-on to Amlodipine in Hypertension https://ClinicalTrials.gov/show/NCT00220233 Completed Daiichi Sankyo, Inc. NA
NCT00220220 Amlodipine as add-on to Olmesartan in Hypertension https://ClinicalTrials.gov/show/NCT00220220 Completed Daiichi Sankyo, Inc. NA
NCT00219141 Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00219141 Completed Novartis 2007-11-30
NCT00219037 Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00219037 Completed Novartis 2005-10-31
NCT00219024 Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension. https://ClinicalTrials.gov/show/NCT00219024 Completed Novartis 2005-06-30
NCT00185185 Olmesartan Medoxomil in Atherosclerosis https://ClinicalTrials.gov/show/NCT00185185 Completed Daiichi Sankyo, Inc. NA
NCT00185172 Olmesartan in Essential Hypertension https://ClinicalTrials.gov/show/NCT00185172 Completed Daiichi Sankyo, Inc. 2005-06-30
NCT00157963 Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) https://ClinicalTrials.gov/show/NCT00157963 Completed Merck Sharp & Dohme Corp. 2006-02-08
NCT00153049 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00153049 Completed Boehringer Ingelheim 2005-06-30
NCT00151827 Olmesartan Medoxomil in Hypertension and Renal Impairment https://ClinicalTrials.gov/show/NCT00151827 Completed Daiichi Sankyo, Inc. 2005-07-31
NCT00139698 Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00139698 Completed Pfizer NA
NCT00138944 Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension https://ClinicalTrials.gov/show/NCT00138944 Completed University of Erlangen-Nürnberg Medical School 2008-05-31
NCT00137124 L-Arginine Metabolism in Essential Hypertension https://ClinicalTrials.gov/show/NCT00137124 Completed University of Erlangen-Nürnberg Medical School 2009-12-31
NCT00131846 Diuretics In the Management of Essential Hypertension (DIME) Study https://ClinicalTrials.gov/show/NCT00131846 Completed Kyoto University 2012-08-31
NCT00130156 Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00130156 Completed Eisai Inc. 2008-09-30
NCT00102141 Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women https://ClinicalTrials.gov/show/NCT00102141 Completed Bayer NA
NCT00092209 Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302) https://ClinicalTrials.gov/show/NCT00092209 Completed Merck Sharp & Dohme Corp. 2002-11-30
NCT00819104 A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components https://ClinicalTrials.gov/show/NCT00819104 Completed AstraZeneca NA
NCT00818883 Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension https://ClinicalTrials.gov/show/NCT00818883 Completed Takeda 2009-11-30
NCT00794885 China Stroke Primary Prevention Trial https://ClinicalTrials.gov/show/NCT00794885 Completed Shenzhen Ausa Pharmed Co.,Ltd 2013-08-31
NCT00741585 Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment https://ClinicalTrials.gov/show/NCT00741585 Completed University of Vigo 2018-06-30
NCT00026065 Hypertension: Prediction of Biofeedback Success https://ClinicalTrials.gov/show/NCT00026065 Completed National Center for Complementary and Integrative Health (NCCIH) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03371797 Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial https://ClinicalTrials.gov/show/NCT03371797 Completed PharmEvo Pvt Ltd 2018-10-01
NCT03310684 Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS) https://ClinicalTrials.gov/show/NCT03310684 Enrolling by invitation Wake Forest University Health Sciences 2020-12-31
NCT03063697 Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure https://ClinicalTrials.gov/show/NCT03063697 Enrolling by invitation Chong Kun Dang Pharmaceutical 2020-12-31
NCT02938910 Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism https://ClinicalTrials.gov/show/NCT02938910 Completed Assistance Publique - Hôpitaux de Paris 2014-10-31
NCT02449811 RAS Peptide Profiles in Patients With Arterial Hypertension https://ClinicalTrials.gov/show/NCT02449811 Completed University Hospital Inselspital, Berne 2018-08-31
NCT02443454 Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation https://ClinicalTrials.gov/show/NCT02443454 Completed Medical University of Warsaw 2015-09-30
NCT02238262 Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals https://ClinicalTrials.gov/show/NCT02238262 Completed Boehringer Ingelheim 2000-12-31
NCT02235415 Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02235415 Completed Boehringer Ingelheim 1999-09-30
NCT02187705 Micardis® in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02187705 Completed Boehringer Ingelheim 2000-05-31
NCT02176850 Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT02176850 Completed Boehringer Ingelheim 2000-05-31
NCT01295021 The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. https://ClinicalTrials.gov/show/NCT01295021 Completed AstraZeneca 2012-02-29
NCT01742702 HaemoDYNAMICs in Primary and Secondary Hypertension https://ClinicalTrials.gov/show/NCT01742702 Recruiting Tampere University 2023-12-31
NCT01392534 Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting https://ClinicalTrials.gov/show/NCT01392534 Completed Bayer 2010-12-31
NCT03855605 Diagnosis of Hypertension by Home Blood Pressure Monitoring https://ClinicalTrials.gov/show/NCT03855605 Recruiting DongGuk University 2019-12-31
NCT03847350 Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT03847350 Completed A.Menarini Asia-Pacific Holdings Pte Ltd 2017-03-23
NCT03841383 Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk https://ClinicalTrials.gov/show/NCT03841383 Completed IRCCS San Raffaele 2019-05-31
NCT03649646 FimasaRtan-basEd BP Targets After Drug SwitcHing https://ClinicalTrials.gov/show/NCT03649646 Recruiting Boryung Pharmaceutical Co., Ltd 2020-09-09
NCT01127139 Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT01127139 Completed Abbott 2011-03-31
NCT01083017 Resistant Arterial Hypertension Cohort Study https://ClinicalTrials.gov/show/NCT01083017 Completed University Hospital, Geneva 2017-05-31
NCT01022515 Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma https://ClinicalTrials.gov/show/NCT01022515 Completed University Hospital, Rouen 2013-12-31
NCT00882947 Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH) https://ClinicalTrials.gov/show/NCT00882947 Completed Bayer 2008-09-30
NCT03708601 Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT) https://ClinicalTrials.gov/show/NCT03708601 Recruiting Beijing Institute of Heart, Lung and Blood Vessel Diseases 2022-08-08
NCT00802542 In-practice Evaluation of Atacand 16mg Antihypertensive Effect https://ClinicalTrials.gov/show/NCT00802542 Completed AstraZeneca 2009-01-31
NCT00638911 Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension https://ClinicalTrials.gov/show/NCT00638911 Completed Boehringer Ingelheim 2009-10-31
NCT00608153 Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide https://ClinicalTrials.gov/show/NCT00608153 Completed AstraZeneca NA
NCT00573742 Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients https://ClinicalTrials.gov/show/NCT00573742 Completed AstraZeneca 2008-02-29
NCT00298129 Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease https://ClinicalTrials.gov/show/NCT00298129 Completed Yokohama City University Medical Center NA
NCT00286884 Heart Rate Variability in White Coat Hypertension and Essential Hypertension https://ClinicalTrials.gov/show/NCT00286884 Completed Regional Hospital Holstebro NA
NCT03473275 Brain BOLD fMRI in Hypertensive and Normotensive Participants https://ClinicalTrials.gov/show/NCT03473275 Recruiting Centre Hospitalier Universitaire Vaudois 2021-03-31
NCT00001527 Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension https://ClinicalTrials.gov/show/NCT00001527 Completed National Institutes of Health Clinical Center (CC) NA
NCT00607633 Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH https://ClinicalTrials.gov/show/NCT00607633 Completed AstraZeneca NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02553512 Helius in Hypertension-I: The UK Hypertension Registry https://ClinicalTrials.gov/show/NCT02553512 Completed Proteus Digital Health, Inc. 2014-12-31
NCT02385721 Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) https://ClinicalTrials.gov/show/NCT02385721 Completed Boryung Pharmaceutical Co., Ltd 2017-07-31